<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="82315">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01903148</url>
  </required_header>
  <id_info>
    <org_study_id>SEN-AEE-2011-01</org_study_id>
    <nct_id>NCT01903148</nct_id>
  </id_info>
  <brief_title>Anemia Management in Chronic Kidney Disease Not on Dialysis Patients After the European Renal Best Practice (ERBP) Working Group Recommendations</brief_title>
  <acronym>ACERCA</acronym>
  <official_title>ANEMIA MANAGEMENT IN CHRONIC KIDNEY DISEASE NOT ON DIALYSIS PATIENTS AFTER THE ERBP WORKING GROUP RECOMMENDATIONS</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundación Senefro</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundación Senefro</source>
  <oversight_info>
    <authority>Spain: Agencia Española de Medicamentos y Productos Sanitarios</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the impact of the last recommendations of the
      European Anemia Working Group ERBP in the anemia management in the achievement of the
      therapeutic goal of Hb 11-12 g/dL.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2011</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Cross-Sectional</study_design>
  <primary_outcome>
    <measure>% Patients Achieving Target Hemoglobin Levels</measure>
    <time_frame>1 day because is a crosssectional study with only a visit</time_frame>
    <safety_issue>No</safety_issue>
    <description>% patients with Hb levels between 11-12 mg/dl</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Hemoglobin Levels Per Type of Patients</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>levels Hb and type of patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Hb&gt;12</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>% Patients With Erythropoiesis Stimulating Agents (ESA) Therapy</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>know the treatments ESA for maintenance of hb levels</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Iron Treatment</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>Patients with supplementary Iron treatment to ESA</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients With Hb&lt;11</measure>
    <time_frame>1 day</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">455</enrollment>
  <condition>ANEMIA</condition>
  <eligibility>
    <study_pop>
      <textblock>
        Adults patients with anemia secondary to chronic kidney disease (CKD) not on dyalisis.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adults patients with anemia secondary to chronic kidney disease (CKD) not on
             dialysis.

          -  Patients starting anemia treatment (naïve) after six months of the last
             recommendations of the European Anemia Working Group ERBP (January 2011).

          -  Patients in treatment who changed from previous ESA treatment since January 2011
             (converted patients

        Exclusion Criteria:

          -  Patients in Erythropoiesis Stimulating Agents (ESA) dose adjustment period.

          -  Kidney transplant patients.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Martinez Castelao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Bellvitge</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aleix Cases, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hospital Clinic de Barcelona</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hospital Puerto Real</name>
      <address>
        <city>Cadiz</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Jerez</name>
      <address>
        <city>Jerez</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínico V. Victoria</name>
      <address>
        <city>Malaga</city>
        <state>Andalucía</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Marques de Valdecilla</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Luz</name>
      <address>
        <city>Toledo</city>
        <state>Castilla la Mancha</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sagrat Cor</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bellvige</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Valld'Hebron</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundación Puigvert</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bellvitge</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica Girona</name>
      <address>
        <city>Gerona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Josep Trueta</name>
      <address>
        <city>Gerona</city>
        <state>Cataluña</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Alicante</name>
      <address>
        <city>Alicante</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Castellón</name>
      <address>
        <city>Castellón</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Fe</name>
      <address>
        <city>Valencia</city>
        <state>Comunidad Valenciana</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arquitecto Marcide</name>
      <address>
        <city>Ferrol</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complexo Hospitalario de Ourense</name>
      <address>
        <city>Orense</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <state>Galicia</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Islas Baleares</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Nuestra Señora De Candelaria</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Islas Canarias</state>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico San Carlos</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital La Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital 12 de Octubre</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 8, 2013</lastchanged_date>
  <firstreceived_date>July 12, 2013</firstreceived_date>
  <firstreceived_results_date>August 22, 2013</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ANEMIA IN CHRONIC KIDNEY DISEASE PATIENTS NOT ON DIALYSIS</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Nephrology Units of 30 Spanish hospitals.</recruitment_details>
      <pre_assignment_details>14 patients were excluded because they didn't fulfill the eligibility criteria</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Patients With Anemia and CKD</title>
          <description>Adults patients with anemia secondary to chronic kidney disease (CKD) not on dialysis.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="441"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Converted Patients</title>
          <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
        </group>
        <group group_id="B2">
          <title>Naïve Patients</title>
          <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="143"/>
                <measurement group_id="B2" value="298"/>
                <measurement group_id="B3" value="441"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="73.5" spread="13.9"/>
                <measurement group_id="B2" value="72.9" spread="12.5"/>
                <measurement group_id="B3" value="73.1" spread="13"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="77"/>
                <measurement group_id="B2" value="152"/>
                <measurement group_id="B3" value="229"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="66"/>
                <measurement group_id="B2" value="146"/>
                <measurement group_id="B3" value="212"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>% Patients Achieving Target Hemoglobin Levels</title>
        <description>% patients with Hb levels between 11-12 mg/dl</description>
        <time_frame>1 day because is a crosssectional study with only a visit</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Converted Patients</title>
            <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
          </group>
          <group group_id="O2">
            <title>Naïve Patients</title>
            <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>% Patients Achieving Target Hemoglobin Levels</title>
            <description>% patients with Hb levels between 11-12 mg/dl</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="42.5" spread="1.3"/>
                  <measurement group_id="O2" value="35.3" spread="1.3"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hemoglobin Levels Per Type of Patients</title>
        <description>levels Hb and type of patients</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <population>n represents the number of participants analyzed for each category respectively (converted patients, naïve patients)</population>
        <group_list>
          <group group_id="O1">
            <title>Converted Patients</title>
            <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
          </group>
          <group group_id="O2">
            <title>Naïve Patients</title>
            <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Hemoglobin Levels Per Type of Patients</title>
            <description>levels Hb and type of patients</description>
            <units>mg/dl</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <sub_title>Hb levels in non diabetics patients, n=79, 163</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.6" spread="1.2"/>
                  <measurement group_id="O2" value="11.5" spread="1.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hb levels in diabetics patients, n=64, 135</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.4" spread="1.3"/>
                  <measurement group_id="O2" value="11.1" spread="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hb levels patients non cardiovasdisease, n=76, 151</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.4" spread="1.2"/>
                  <measurement group_id="O2" value="11.5" spread="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hb levels patients cardiovasculardisease, n=67,147</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.7" spread="1.4"/>
                  <measurement group_id="O2" value="11.2" spread="1.2"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hb levels patients noncerebrovadisease, n=125, 265</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.6" spread="1.2"/>
                  <measurement group_id="O2" value="11.3" spread="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hb levels patients with cerebrovadisease n=18, 33</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.4" spread="1.7"/>
                  <measurement group_id="O2" value="11.4" spread="1.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hb levels patients non cancer, n=129,257</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.5" spread="1.3"/>
                  <measurement group_id="O2" value="11.3" spread="1.3"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Hb levels patients with cancer n=14, 41</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="11.6" spread="1.2"/>
                  <measurement group_id="O2" value="11.3" spread="1.2"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Hb&gt;12</title>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Converted Patients</title>
            <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
          </group>
          <group group_id="O2">
            <title>Naïve Patients</title>
            <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patients With Hb&gt;12</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="52"/>
                  <measurement group_id="O2" value="71"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>% Patients With Erythropoiesis Stimulating Agents (ESA) Therapy</title>
        <description>know the treatments ESA for maintenance of hb levels</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Converted Patients</title>
            <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
          </group>
          <group group_id="O2">
            <title>Naïve Patients</title>
            <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>% Patients With Erythropoiesis Stimulating Agents (ESA) Therapy</title>
            <description>know the treatments ESA for maintenance of hb levels</description>
            <units>percentage of participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <sub_title>Mircera</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="74.1"/>
                  <measurement group_id="O2" value="83.4"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Darbepoetin</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="19.6"/>
                  <measurement group_id="O2" value="13.1"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Epoetin alfa</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="2.1"/>
                  <measurement group_id="O2" value="1.7"/>
                </measurement_list>
              </category>
              <category>
                <sub_title>Epoetin beta</sub_title>
                <measurement_list>
                  <measurement group_id="O1" value="4.2"/>
                  <measurement group_id="O2" value="1.7"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Iron Treatment</title>
        <description>Patients with supplementary Iron treatment to ESA</description>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Converted Patients</title>
            <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
          </group>
          <group group_id="O2">
            <title>Naïve Patients</title>
            <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Iron Treatment</title>
            <description>Patients with supplementary Iron treatment to ESA</description>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="68"/>
                  <measurement group_id="O2" value="175"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patients With Hb&lt;11</title>
        <time_frame>1 day</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Converted Patients</title>
            <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
          </group>
          <group group_id="O2">
            <title>Naïve Patients</title>
            <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="143"/>
                  <measurement group_id="O2" value="298"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Patients With Hb&lt;11</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="38"/>
                  <measurement group_id="O2" value="98"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Converted Patients</title>
          <description>Patients in treatment who changed from previous ESA treatment since January 2011</description>
        </group>
        <group group_id="E2">
          <title>Naïve Patients</title>
          <description>Patients starting anemia treatment (naïve) after six months of the last recommendations of the Anemia Working Group of ERBP (January 2011)</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac insufficiency left side</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hipercalcemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0.6</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="143"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Precordial pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>auricular fibrilation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Urinary infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>orquiepididimitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="143"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="298"/>
              </event>
              <event>
                <sub_title>Change sounds nefrostomia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="143"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="298"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Alberto Martínez Castelao</name_or_title>
      <organization>Hospital de Bellvitge</organization>
      <phone>610 459 262</phone>
      <email>albertomcastelao@gmail.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
